Cisplatin in ovarian cancer

A 4-year follow-up of comparison of a combination of cyclophosphamide with either 50 mg/m or 100 mg/m of cisplatin in ovarian cancer has been reported (76). Peripheral neuropathy was dose-limiting and persistent. 

Carboplatin is a cytotoxic platinium complex structurally related to cisplatin, which antitumor activity in vitro is qualitatively similar to that of cisplatin. Comparative trials with carboplatin alone or in combination with other chemotherapeutic agents suggest comparable efficacy with cisplatin in ovarian cancer. As with cisplatin, nausea and vomiting occur in many patients but symptoms are usually delayed for several hours and mild to moderate in severity. The dose limiting toxicity of carboplatin is myelosuppression enhanced by renal impairment, previous chemotherapy or in older patients. 

---